We take part in a clinical trial on geographic atrophy of the retina
With a global outlook. Miranza Instituto Gómez-Ulla has participated in an international clinical trial to evaluate the efficacy and safety of FWY003, an innovative oral treatment for patients with geographic atrophy secondary to age-related macular degeneration (AMD), one of the leading causes of severe vision loss in people over the age of 50.
The main distinguishing feature of this study is that FWY003 could become the first orally administered treatment for geographic atrophy, offering an alternative to the therapies currently available for this form of AMD, which are based on periodic intravitreal injections and are currently administered outside Europe.
“The development of an oral alternative for geographic atrophy would represent a highly significant advance in the treatment of this disease. At present, the available therapeutic options require frequent intravitreal injections, placing a considerable clinical and emotional burden on many patients, particularly older adults,” explains Maximino Abraldes, a macula, retina and vitreous specialist at Miranza Instituto Gómez-Ulla.
The doctor also points out that having an oral treatment available “could significantly improve patient convenience, treatment adherence and, consequently, the long-term management of the disease.”
The Only Centre in Galicia and One of Just Three in Spain
Miranza Instituto Gómez-Ulla is the only centre in Galicia participating in this international clinical trial and one of only three selected across Spain. The study will assess whether this new drug can slow the progression of the characteristic lesions of the disease and preserve patients’ visual function, or at least delay disease progression. The trial is expected to include approximately 272 patients worldwide and will run for up to 22 months. The investigational drug targets the biological pathway involved in the inflammation and progression of age-related macular degeneration. According to the study protocol, the aim is to achieve potent and sustained inhibition of this inflammatory pathway through once-daily oral administration.